133 results on '"Frank, Elizabeth S."'
Search Results
2. Exploring anxiety as an influencing factor of the impact of exercise and mind-body prehabilitation on cognitive functioning among women undergoing breast cancer surgery.
3. Recommendations for Obesity Clinical Trials in Cancer Survivors: American Society of Clinical Oncology Statement
4. TBCRC 057: Survey about willingness to participate in cancer clinical trials during the pandemic.
5. Supplementary Figures from Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia
6. Data from Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia
7. Supplementary Methods from Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia
8. Supplementary Tables from Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia
9. Supplemental Table 1 from A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
10. Supplemental Table 4 from A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
11. Supplemental Table 2 from A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
12. Supplemental Figure 5 from A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
13. Supplemental Figure 1 from A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
14. Supplemental Table 3 from A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
15. Supplemental Methods from A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
16. Supplemental Figure 3 from A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
17. Supplemental Figure Legends from A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
18. Supplemental Figure 2 from A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
19. Supplemental Figure 4 from A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
20. Surveillance Imaging after Primary Diagnosis of Ductal Carcinoma in Situ
21. TBCRC 057: An online survey about anxiety and willingness to participate in breast cancer clinical trials during the COVID-19 pandemic.
22. Comparing an operation to monitoring, with or without endocrine therapy (COMET), for low-risk ductal carcinoma in situ (DCIS).
23. Association of Regional Intensity of Ductal Carcinoma In Situ Treatment With Likelihood of Breast Preservation
24. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update
25. “Is it cancer or not?” A qualitative exploration of survivor concerns surrounding the diagnosis and treatment of ductal carcinoma in situ
26. Effects of Maternal Status on the Movement and Mortality of Sterilized Female White-Tailed Deer
27. Surgical Technique for Tubal Ligation in White-Tailed Deer (Odocoileus virginianus)
28. Exploring the impact of exercise and mind–body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery
29. Prospective clinical experience with research biopsies in breast cancer patients
30. Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab (P+T) in the APHINITY trial.
31. Disparities in surveillance imaging after breast conserving surgery for primary DCIS.
32. Abstract PD5-03: Ipsilateral invasive cancer risk after diagnosis with ductal carcinoma in situ in patients with and without index surgery: The effects of endocrine therapy and radiation treatment
33. Perceptions of patients with early stage breast cancer toward research biopsies
34. BURROWING AND DENNING HABITS OF A CAPTIVE COLONY OF THE UTAH PRAIRIE DOG
35. Multidisciplinary considerations in the treatment of triple‐negative breast cancer
36. Abstract B10: Rhabdomyosarcoma requires MYC family genomic events to pathogenically subvert core-regulatory circuitry
37. Abstract PR11: EP300 controls the oncogenic enhancer landscape of high-risk neuroblastoma
38. Ipsilateral invasive cancer risk after diagnosis with ductal carcinoma in situ (DCIS): Comparison of patients with and without index surgery.
39. Abstract P1-21-07: The Patient-reported Outcomes after Routine Treatment of Atypical Lesions (PORTAL) study: Pain, psychosocial wellbeing, and quality of life among women undergoing guideline concordant care for DCIS vs. active surveillance for in situ and atypical lesions
40. Commentary: Creating a patient‐centered decision aid for ductal carcinoma in situ
41. Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia
42. Patient‐reported outcomes in the Translational Breast Cancer Research Consortium
43. Perceptions of patients with early stage breast cancer toward research biopsies.
44. Patient‐preferred outcomes measurement after post‐mastectomy radiation therapy and immediate reconstruction
45. A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
46. Resistance Mechanisms to SYK Inhibition in AML
47. Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors.
48. Patient-reported outcomes in the Translational Breast Cancer Research Consortium.
49. Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras
50. Estrogen-receptor status and risk of contralateral breast cancer following DCIS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.